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Abstract
Asthma and chronic obstructive pulmonary disease (COPD) are highly
prevalent chronic obstructive lung diseases with an associated high
burden of disease. Asthma, which is often allergic in origin, frequently
begins in infancy or childhood with variable airflow obstruction and
intermittent wheezing, cough, and dyspnea. Patients with COPD, in
contrast, are usually current or former smokerswhopresent after the age
of 40 years with symptoms (often persistent) including dyspnea and a
productive cough. On the basis of age and smoking history, it is often
easy to distinguish between asthma andCOPD.However, some patients
have features compatible with both diseases. Because clinical studies
typically exclude these patients, their underlying disease mechanisms
and appropriate treatment remain largely uncertain. To explore the
status of and opportunities for research in this area, the NHLBI, in
partnership with the American Thoracic Society, convened a workshop
of investigators in San Francisco, California on May 14, 2016. At the
workshop, current understanding of asthma–COPD overlap was
discussed among clinicians, pathologists, radiologists, epidemiologists,
and investigators with expertise in asthma and COPD. They considered
knowledge gaps in our understanding of asthma–COPD overlap and
identified strategies and research priorities that will advance its
understanding. This report summarizes those discussions.
Keywords: asthma; chronic obstructive pulmonary disease;
overlap
Asthma and chronic obstructive pulmonary
disease (COPD) are highly prevalent and
heterogeneous conditions with an associated
high disease burden. Physiologically, asthma
displays bronchial hyperresponsiveness
(BHR) and variable expiratory airflow
limitation, which is partially or fully
reversible with a bronchodilator, whereas
COPD displays chronic airflow limitation
that is not fully reversible with a
bronchodilator. A patient’s age and
smoking history often easily separate
asthma and COPD, but some patients have
features compatible with both diseases. To
describe this condition, investigators
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introduced the term “ACOS”
(asthma–COPD overlap syndrome) (1).
Because one of the major conclusions of the
workshop was that this condition does not
represent a single discrete disease entity, the
modified term “asthma–COPD overlap”
(ACO) will be used throughout this report.
ACO may be used to describe patients
with asthma who have features of COPD,
specifically incompletely reversible
(i.e., fixed) airflow obstruction, as was
observed in up to 20% of patients with
asthma (2). Such nonsmoking patients with
asthma with fixed airflow obstruction may
appear comparable to patients with COPD,
with a greater rate of decline in lung
function over 5 years than patients with
asthma with reversible obstruction (3).
However, nonsmoking patients with
asthma with fixed airflow obstruction
demonstrate significantly more blood,
sputum, and bronchoalveolar lavage fluid
eosinophilia than similarly obstructed
patients with COPD (4). In that study,
higher sputum eosinophil counts predicted
greater lung function decline in asthma,
whereas higher sputum neutrophils were
associated with lung function decline in
COPD.
ACO may also be used to describe
patients with COPD with features of
asthma, such as bronchodilator
responsiveness (BDR) and/or BHR. About
50% of patients with COPD show significant
BDR (5), but up to 90% have BHR,
especially women with COPD (6). BDR
may predict the response to treatment in
patients with COPD. For example, FEV1
improved to a larger extent after 8 weeks of
treatment with fluticasone/salmeterol in
patients with COPD with versus without
BDR (7) and after 2 to 3 months of inhaled
corticosteroids (ICS) in a computed
tomography (CT)-defined nonemphysema
phenotype with greater BDR than in two
emphysema phenotypes (8). Although BHR
is clearly influenced by FEV1 itself (9),
multivariate regression analyses showed
that more severe BHR in COPD was
independently associated with airway
inflammation (6). Results from two large
cohorts demonstrated that BHR is
associated with greater mortality and rate of
FEV1 decline and markers of systemic
inflammation in COPD (10). Thus, patients
with COPD who have features of asthma
may have a poorer long-term clinical course
than those without.
ACO: Clinical Features
Although classical asthma and COPD are
easily distinguished, patients often present
to primary care providers with nonspecific
respiratory symptoms or with similarly
reduced lung function despite differing
clinical histories, including severe childhood
asthma with impaired lung development,
asthma in a smoker, long-standing asthma
with irreversible airflow obstruction, and
emphysema with atopy and variable
symptoms of airway disease. This variability
suggests that multiple different mechanisms
may drive the presentation of these
phenotypes of airway disease.
Patients with features of ACO have
greater symptom burden and physical
impairment, more hospitalizations (11),
and a worse quality of life (12) than those
with asthma or COPD alone. In the
COPDGene study, the 13% of patients
with COPD who reported having had a
doctor diagnosis of asthma at younger
than 40 years of age had similar lung
function to those with COPD alone but
had worse quality of life, more frequent
exacerbations, and more gas trapping on
CT scan (13). However, despite this
clinical significance, asthma and COPD
guidelines can only poorly address this
population, because they are based on
studies from which most patients with
ACO were excluded. Indeed, guidelines
provide opposite safety-based
recommendations about
pharmacotherapy. In asthma, ICS are
recommended to reduce the risk of
exacerbations and mortality, but in
COPD, ICS are reserved for patients with
a history of repeated exacerbations. Long-
acting bronchodilators (without ICS) are
initial therapy in COPD, but long-acting
b-agonists alone are contraindicated in
asthma because of the risk of death. Few
pharmacotherapy studies are underway in
overlap populations. Although this
evidence is being obtained, clinicians
must be provided with interim clinical
advice on the basis of safety
considerations (14), such as was
published by the Global Initiative for
Asthma (GINA) and the Global Initiative
for Chronic Obstructive Lung Disease
(GOLD) (15).
It is hence proposed to use the term
ACO as an interim clinical label, to
identify at-risk patients on the basis of
clinical features of both asthma and
COPD to safely manage patients until
evidence about mechanisms and
targeted treatments emerges. For clinical
practice, GINA and GOLD suggested a
syndromic approach to identify
patients with typical asthma, typical
COPD, and overlap, on the basis of the
relative number of clinical features of
asthma and COPD and results from
spirometry (15). That approach was not
endorsed by the discussants of this
workshop.
In many retrospective studies, the
distinction of asthma fromCOPDwas based
on spirometry, including bronchodilator
reversibility and post-bronchodilator
FEV1/FVC less than 0.70 or less than the
lower limit of normal. Most have limited
At a Glance Commentary
Scientific Knowledge on the
Subject: Asthma and chronic
obstructive pulmonary disease
(COPD) are highly prevalent
conditions, with an associated high
disease burden. On the basis of age and
smoking history, it is often easy to
distinguish between asthma and
COPD. However, some patients have
features compatible with both diseases.
Because clinical studies typically
exclude these patients, their underlying
disease mechanisms and appropriate
treatment remain largely uncertain. To
explore the status of and opportunities
for research in this area, the NHLBI,
in partnership with the American
Thoracic Society, convened a
workshop of investigators.
What This Study Adds to the
Field: At the workshop, current
understanding of asthma–COPD
overlap was discussed among
clinicians, pathologists, radiologists,
epidemiologists, and investigators with
expertise in asthma and COPD. They
considered knowledge gaps in our
understanding of asthma–COPD
overlap and identified strategies and
research priorities that will advance its
understanding. One of the major
conclusions of the workshop was that
this condition does not represent a
single discrete disease entity.
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“asthma” to lifetime nonsmokers, or
ex-smokers with less than 5 to 10 pack-year
history. With physiological criteria alone,
the prevalence of ACO may be
overestimated, because up to 50% of
patients with COPD have bronchodilator
reversibility greater than 200 ml and greater
than 12% (5, 7). In addition, patients with
asthma whose physiology does not revert to
normal despite multiple treatments have
been long recognized. These patients,
described as having “fixed” airflow
limitation, have been identified objectively
with unbiased clustering approaches in the
Severe Asthma Research Program (SARP).
In SARP, fixed obstruction is associated
with a mixed inflammatory process and
high inhaled and systemic corticosteroid
use and side effects (16). Despite this
inability to improve to “normal” with
bronchodilators, more than 12%
reversibility is sometimes present.
One approach to minimizing the effect
of preconceptions about classification of
airway disease and to develop “unbiased”
subgroups is to apply cluster analysis. One
analysis of adults with symptomatic airway
obstruction identified two distinct clusters
of patients with marked bronchodilator
reversibility and peak flow variability; one
had late-onset disease, a heavy smoking
history, and emphysema, and the other had
moderate to severe allergic asthma (17).
In SARP, cluster analysis identified five
clusters of nonsmoking patients with
asthma, where cluster 5 had characteristics
associated with COPD (18). More studies of
mechanisms or endotypes driving these
phenotypes are needed.
Role of Imaging in ACO
Imaging can contribute to the evaluation of
asthma and COPD by assessing airway
narrowing and wall thickness and the
presence, pattern, and severity of
emphysema and identifying and
quantifying expiratory air trapping.
Although CT is the most widely used
technique, magnetic resonance imaging
(MRI) can provide additional information
about the size of distal airspaces and the
presence of ventilation defects. Primary
measures of emphysema are the percent of
lung voxels less than 2950 Hounsfield
units (LAA2950 HU) and the 15th
percentile of lung attenuation (PERC15)
(19). Imaging can be used for disease
identification and stratification and for
exploring image-based biomarkers or as an
efficacy outcome in therapeutic trials in
patients with ACO.
Small airways less than 2 mm in
diameter are believed to be the primary
site of airflow obstruction in both asthma
and COPD (20, 21). These small airways
include a portion of both the conducting
airways and the acinar airways and are
currently below the limit of CT
resolution.
Analyses of large airway morphology,
measures of central airway wall thickness,
lumen area, and the wall area percent
(1003wall area/total bronchial area) have
consistently demonstrated in smokers and
those with COPD to be associated with
histopathologic measures of remodeling
and highly correlated with relevant
measures of disease severity (22). The
strength of these correlations increases
when more peripheral airways are
measured (22), possibly reflecting either
small airway disease or native airway
structure (23) important to disease
pathogenesis.
MRI using inhaled hyperpolarized
helium or xenon offers the ability to directly
visualize pulmonary ventilation, and
apparent gas diffusion can provide a
measurement of the size of distal airspaces
in emphysema (24). MRI may therefore
provide a sensitive marker of early small
airway abnormality.
Indirect assessment of the small
airways via CT scan has also been
investigated. One option is to measure gas
trapping by quantifying the percent of
voxels less than2856 HU on expiratory CT
scan (25). Another method to measure gas
trapping is to compute the ratio of
expiratory to inspiratory mean lung density
(26). Both methodologies in COPD cannot
completely distinguish areas of small airway
disease from areas of emphysema. Image
registration that matches inspiratory and
expiratory lung helps to overcome this
problem (27), although this approach
increases radiation exposure. Measurement
of functional small airway disease using this
technique can predict progression of
airflow obstruction in COPD (28).
Although CT measures of decreased
lung attenuation are often used as a
surrogate for emphysema, patients with
asthma may also have decreased lung
attenuation (29), presumably because of
overinflated lung parenchyma. This
technique can differentiate asthmatic
subgroups with distinctive clinical
phenotypes (30).
Although imaging is unlikely to provide
all the information needed to stratify a patient
as having asthma, COPD, or overlap, CT
evidence of significant small airway
abnormality in the setting of supportive
clinical characteristics and lack of significant
emphysemawould be consistent with overlap.
Quantitative CT metrics using inspiratory
and expiratory images may also hold promise
as a surrogate endpoint in ACO. In the future,
MRI may also provide useful information
regarding the nature of airway obstruction.
Is ACO Traceable to Early
Infancy?
Regardless of whether ACO develops in
individuals with severe asthma who
advance to fixed obstruction or in adult
smokers who had childhood asthma, its
origins may begin in childhood (31). In
the Childhood Asthma Management
Program (CAMP) study, FEV1/FVC ratio
was significantly lower in subjects with
asthma than in control subjects, and
deficits were already present at age 6 years
(32). Interestingly, 11% of CAMP
participants with asthma had a level
of lung function consistent with COPD
in early adult life. The Busselton
longitudinal study suggested that
smoking may have more severe effects on
lung function in subjects with a baseline
history of asthma (33).
In a long-term cohort study, children
with asthma were six times more likely to
have airflow limitation consistent with
COPD at age 60 to 65 years than those
without childhood asthma (34). The extent
of fixed airflow obstruction in nonsmoking
adults who had childhood asthma was
equivalent to that observed with a 33 pack-
year history of smoking (35). In subjects
with asthma in the Tucson Children’s Study,
post-bronchodilator FEV1/FVC ratio at age
22 years was linearly related to age of onset
of the disease (36). The lowest lung function
in patients with current asthma was
observed in those who were first diagnosed
before age 6 years Airflow limitation and
BHR were already observed by age 6 years in
subjects with onset of asthma in early adult
life (36). These observations lead to the
questions of when fixed obstruction starts,




preventing childhood asthma could have a
substantial impact on ACO and long-term
survival.
Adults with a history of wheezing lower
respiratory illnesses due to respiratory
syncytial virus (RSV) and who smoked are
1.6 times more likely to have a diagnosis of
asthma than those without a smoking history
(37). Early life RSV-related events may thus
synergize with smoking in predisposing to
ACO. Interestingly, wheezing lower
respiratory illnesses due to RSV in early life
may predispose to harboring RSV
chronically (38), and RSV has been detected
in the airways of patients with COPD (39),
suggesting that cigarette smoke may
reactivate RSV, enhancing its deleterious
effects. Additional data link respiratory viral
infections to persistent airway inflammation
and mucus production in mouse models of
postviral airway disease. One model, using
mouse parainfluenza virus, has identified
three new immune pathways of airway
disease (40) and showed that IL-33/IL-33
receptor signaling was required for Il13 and
mucin gene expression and that Il33 gene
expression was localized to a virus-induced
subset of airway epithelial cells linked to
progenitor function (41). Patients with
COPD tissue samples confirmed IL33
gene expression associated with IL13 and
mucin gene expression. A similar cascade
has been found in virus-induced asthma
exacerbations (42). These findings support a
unified model that links the acute antiviral
response to persistent and progressive
chronic airway disease.
Another model using mice deficient for
the myeloid receptor TREM-2 (triggering
receptor expressed on myeloid cells) and the
mouse parainfluenza virus showed that
soluble TREM-2 prompted feed-forward
expansion of immune cells required for
IL-13 production. This mechanism may
explain how infection leads to type 2
immune disease (43). Finally, a third model
revealed that the mouse chloride channel
accessory 1 gene was associated with
increased mucin (MUC5AC) gene
expression, and studies in humans defined
a signaling pathway from human Clca1
to mitogen-activated protein kinase 13 that
was responsible for IL-13–driven mucus
production in human airway epithelial cells
(44). These results revealed a new pathway
for regulating mucus production and
suggest that development of a distinct type
2 immune response may drive both asthma
and COPD.
Mucociliary Clearance,
Chronic Bronchitis, and ACO
COPD and asthma share chronic bronchitis
(CB) as a common clinical-pathological
component. CB presents clinically with
cough and sputum production and
exhibits features of airway remodeling,
inflammation, and mucus obstruction. This
suggests that failure of mucociliary clearance
is central to CB pathogenesis. It has recently
been proposed that the mechanisms
underlying successful mucus clearance rely
on the airway mucociliary apparatus being
comprised of two hydrogels: (1) a tethered
mucin periciliary layer (PCL), and (2) a
mobile secreted mucin (MUC5AC and
MUC5B) mucus layer located on top of the
PCL (45). The two hydrogels compete for
water as a function of their relative osmotic
pressures (water-drawing powers). In
health, the PCL gel is more concentrated
than the mucus layer, ensuring that the
PCL is well hydrated and lubricates mucus
flow over airway surfaces. In disease, a
decrease of airway surface liquid or mucin
hypersecretion onto airway surfaces
produces a “hyperconcentrated”
(dehydrated) mucus layer. In this diseased
state, the mucus layer draws water from the
PCL, producing osmotic compression of
cilia that can lead to mucus transport
cessation, chronic inflammation,
obstruction, and bacterial infection.
There is promise in defining features
of ACO on the basis of the mucin
characteristics that are features of cigarette
smoking–induced COPD versus asthma.
Biochemical studies have identified
MUC5B as the dominant secreted mucin in
cigarette smoke–induced COPD (46), and a
fraction of patients with asthma have been
reported to exhibit high airway mRNA
expression levels of MUC5AC with
evidence for a reduction in MUC5B (47).
To better understand the contributions of
mucins to ACO, it will be necessary to
know the specific features of mucins that
are characteristic of CB in “pure” COPD
and asthma.
ACO: Cell and Molecular
Biomarkers and Their
Therapeutic Implications
Sputum cytology has identified four major
phenotypes of cellular inflammation in
airway disease: neutrophilic, eosinophilic,
mixed granulocytic, and paucigranulocytic.
COPD is typically more neutrophilic and
asthmamore eosinophilic. However, there is
heterogeneity with each condition and
overlap between both conditions. For
example, in asthma, some phenotypes are
eosinophilic and others are neutrophilic or
combined eosinophilic and neutrophilic
(16, 48), whereas in COPD, 10 to 40% of
subjects have sputum eosinophilia (49).
With some variability over time and in
response to therapies, many subjects exhibit
relative phenotype stability, suggesting
consistent underlying molecular
mechanisms. To further understand the
inflammatory networks, cluster analysis of
sputum cytokines has been undertaken
in asthma and COPD alone and in
combination (50). This research has
revealed three biological clusters: a type-2
inflammatory group, which, although
asthma predominant, includes patients with
COPD; a proinflammatory group driven
largely by IL-1b and tumor necrosis factor-
a which is present in both asthma and
COPD; and a COPD-predominant group
characterized by a mixed granulocytic
response with elevated sputum IL-6 and
C-C motif chemokine ligand 13 (50). In the
stable state, the inflammatory pattern
predicts response to therapy with a higher
blood and sputum eosinophilia associated
with greater short-term response to inhaled
(51) and oral corticosteroids (52) and novel
biologics targeting IL-5 (53). Management
algorithms using sputum eosinophil counts
to guide corticosteroid therapy reduce
exacerbations in both asthma and COPD
(54, 55). In contrast, lack of a blood
eosinophilia was associated with an
improved response to macrolide antibiotics
in asthma (56). These findings point to
the potential for targeted treatment in
the future.
As in COPD, numerous studies have
shown that some patients with severe
asthma have neutrophilic airway
inflammation with air trapping and
higher levels of proteases associated with
COPD (57). Additional studies have reported
neutrophilia, either alone or in combination
with eosinophilia, in asthma (16, 48). The
majority of patients with asthma and sputum
neutrophilia are taking high-dose inhaled or
even systemic corticosteroids, which prevent
apoptosis of neutrophils, potentially
contributing to their presence, and making it
more difficult to address causality (58). In
addition, neutrophilia appears to be highly
ATS/NHLBI WORKSHOP
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variable and not consistently associated with
smoking (59), and studies aimed at reducing
neutrophilia in severe asthma have not
shown efficacy (60).
Technologies to profile whole
genomes, proteomes, and metabolomes are
evolving quickly and have the potential to
distinguish subgroups within these
complex diseases on a molecular level (47,
61). Gene expression microarray studies
suggest an asthma subgroup that has
airway epithelial gene expression markers
of a heightened type-2 immune response,
classically believed to be the main
inflammatory pathway in asthma (47).
This subgroup, called “type-2–high
asthma,” manifests exaggerated airway
hyperresponsiveness and a better response
to ICS. Similar analyses applied to COPD
cohorts show significant concordance in
gene expression changes in lung tissue
between asthma and COPD (62). This
overlap in gene expression changes suggests
shared mechanisms may be leading to
airflow obstruction in the two diseases.
Given that the type-2 immune response is
more typical of asthma, investigators
assessed whether a type-2 gene expression
signature identifies a molecular phenotype
of COPD with asthma-like characteristics,
which would represent a biologically
defined ACO subgroup. In these studies,
increased airway obstruction, airway tissue,
and blood eosinophils and greater response
to inhaled corticosteroids were associated
with epithelial and tissue markers of
asthmatic type-2 inflammation in COPD.
Importantly, these patients did not bear a
clinical history of asthma. These findings
are promising, as they show that type-2
eosinophilic inflammation is a useful
biomarker to guide consideration of ACO
in patients otherwise believed to have
COPD. Analysis and integration of large,
longitudinal datasets of molecular,
immunologic, and metabolic
characteristics, coupled with measures
of airway exposures and the microbiome,
hold promise for identifying new shared
biomarkers and treatment targets for
both asthma and COPD. With this
understanding, precision medicine
may be realized for individuals with
ACO.
Conclusions
Participants to the workshop did not think it
useful at this time to develop a single,
universal definition of ACO for diagnosis
and treatment. Instead, discussions focused
on reviewing the evidence that features of
asthma and COPD may coexist at
epidemiological, phenotypic, and biological
levels and that the presence of overlapping
Table 1. Workshop Recommendations
Epidemiological and clinical research
d Undertake longitudinal studies in broad populations to better define the prevalence of ACO and its course.
d Phenotype asthma and COPD with respect to specific cellular or biologic processes.
d Clinical trials should include and stratify smoking patients with asthma, especially for studies involving targeted therapies.
d Assess inhaled corticosteroid efficacy in patients who have asthma and persistent airflow limitation.
d Investigate which COPD subgroup(s) has favorable response to ICS.
d Determine when fixed airflow limitation develops (i.e., childhood, adulthood, or both) and what drives its development.
d Assess structural and functional airway disease using imaging and investigate how these features relate to diagnosis and
responsiveness to interventions in asthma, ACO, or COPD.
d Study the applicability of imaging measures as surrogate endpoints in clinical trials.
d Perform MRI studies of the nature of airway obstruction in ACO.
d Link respiratory health with genetic ancestry and the effects of acculturation to better understand respiratory health in underrepresented
populations.
d Consider the effects of social determinants of health, both individually and at the population level, and socioeconomic inequality in
driving asthma, COPD, and ACO.
d Understand the role of comorbidities in ACO.
Basic and applied research
d Identify specific gene signatures in lung cells that are associated with “fixed” airflow limitation, neutrophilia, and smoking.
d Conduct mechanistic studies to better understand the interplay of inflammatory and remodeling pathways and their functional impact in
ACO.
d Investigate the role of RSV and other respiratory viral infections in airflow limitation.
d Address the role of respiratory viral infections in initiating the type-2 immune response and mucus cell metaplasia.
d Use multilevel systems biology approaches (including genetics, gene expression, and proteomics) to provide insights into disease
mechanisms underlying ACO and inform phenotyping.
d Understand the utility and role of mucin subtypes (especially MUC5AC and MUC5B) in defining and contributing to airway disease in
asthma, COPD, and ACO.
d Determine the influence of host genetics and the environment on the development of biological phenotypes.
d Investigate the stability of phenotypes of airway disease.
d Define whether these phenotypes confer a different natural history/future risk and response to therapies.
d Discover and develop new and more precise therapeutics for the airway disease in ACO.
Definition of abbreviations: ACO = asthma–chronic obstructive pulmonary disease overlap; COPD = chronic obstructive pulmonary disease; ICS = inhaled




features has clinical significance. Several
research themes emerged, mainly driven by
the need to better understand the biology
and pathophysiology of ACO and develop
precise treatments for subtypes. In
addition to biological factors, it will be
important in future studies to address the
role of race and ethnicity, socioeconomic
status, and acculturation, considering that
genetic ancestry, a proxy for genetic
variation, can possibly be leveraged to
improve diagnostic clinical accuracy and
identify new genetic risk factors (63). The
participants of the workshop identified
high-priority research needs and developed
specific research recommendations that
could foster rapid advances toward disease
preemption and personalized therapy.
These recommendations are described in
Table 1 as a guideline for further studies of
ACO. n
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61. Faner R, Cruz T, Casserras T, López-Giraldo A, Noell G, Coca I, Tal-
Singer R, Miller B, Rodriguez-Roisin R, Spira A, et al. Network
analysis of lung transcriptomics reveals a distinct b-cell signature in
emphysema. Am J Respir Crit Care Med 2016;193:1242–1253.
62. Christenson SA, Steiling K, van den Berge M, Hijazi K, Hiemstra PS,
Postma DS, Lenburg ME, Spira A, Woodruff PG. Asthma-COPD
overlap; clinical relevance of genomic signatures of type 2
inflammation in chronic obstructive pulmonary disease. Am J Respir
Crit Care Med 2015;191:758–766.
63. Pino-Yanes M, Thakur N, Gignoux CR, Galanter JM, Roth LA, Eng C,
Nishimura KK, Oh SS, Vora H, Huntsman S, et al. Genetic ancestry
influences asthma susceptibility and lung function among Latinos. J
Allergy Clin Immunol 2015;135:228–235.
ATS/NHLBI WORKSHOP
ATS/NHLBI Workshop 381
 
